Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) FCF Margin (2016 - 2025)

Ptc Therapeutics has reported FCF Margin over the past 14 years, most recently at 22.25% for Q4 2025.

  • Quarterly results put FCF Margin at 22.25% for Q4 2025, down 943.0% from a year ago — trailing twelve months through Dec 2025 was 40.58% (up 5796.0% YoY), and the annual figure for FY2025 was 40.58%, up 5394.0%.
  • FCF Margin for Q4 2025 was 22.25% at Ptc Therapeutics, up from 33.05% in the prior quarter.
  • Over the last five years, FCF Margin for PTCT hit a ceiling of 73.84% in Q1 2025 and a floor of 104.28% in Q4 2022.
  • Median FCF Margin over the past 5 years was 33.35% (2025), compared with a mean of 29.3%.
  • Biggest five-year swings in FCF Margin: tumbled -6083bps in 2021 and later skyrocketed 6981bps in 2023.
  • Ptc Therapeutics' FCF Margin stood at 46.94% in 2021, then plummeted by -122bps to 104.28% in 2022, then surged by 67bps to 34.47% in 2023, then skyrocketed by 63bps to 12.82% in 2024, then tumbled by -74bps to 22.25% in 2025.
  • The last three reported values for FCF Margin were 22.25% (Q4 2025), 33.05% (Q3 2025), and 33.35% (Q2 2025) per Business Quant data.